NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT07385846 2026-02-04
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
University of Cincinnati
Phase 1 Not yet recruiting
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04201873 2025-08-22
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02530502 2023-11-18
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Terminated
NCT03726515 2023-06-22
CART-EGFRvIII + Pembrolizumab in GBM
University of Pennsylvania
Phase 1 Completed
NCT05700955 2023-01-26
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
University of Louisville
Phase 1 Unknown